Henan Taloph Pharmaceutical StockLtd Valuation
Is 600222 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 600222 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 600222 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 600222 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600222?
Other financial metrics that can be useful for relative valuation.
| What is 600222's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥2.97b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 27.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 600222's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.1x | ||
300452 Anhui Sunhere Pharmaceutical ExcipientsLtd | 19x | 16.4% | CN¥3.0b |
300583 Shandong Sito Bio-technology | 46.9x | n/a | CN¥2.9b |
002864 Shaanxi Panlong Pharmaceutical Group Limited By Share | 28.2x | n/a | CN¥3.0b |
002873 Guiyang Xintian PharmaceuticalLtd | 30.5x | 26.6% | CN¥3.0b |
600222 Henan Taloph Pharmaceutical StockLtd | 68.2x | n/a | CN¥3.0b |
Price-To-Earnings gegen Gleichaltrige: 600222 ist auf der Grundlage des Price-To-Earnings Verhältnisses (67.5x) im Vergleich zum Durchschnitt der Vergleichsgruppe (30.5x) teuer.
Price to Earnings Ratio vs Industry
How does 600222's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 600222 ist teuer, wenn man sein Price-To-Earnings Verhältnis (67.5x) mit dem CN Pharmaceuticals Branchendurchschnitt (27.2x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 600222's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 68.2x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von 600222 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.